Hypotension Treatment Market Size was valued at USD 0.87 Billion in 2023. The Hypotension Treatment market industry is projected to grow from USD 0.95 Billion in 2024 to USD 1.766 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.06% during the forecast period (2024 - 2032).Stress and lifestyle diseases are made worse by the growing population, which increases the need for cutting-edge therapies are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for hypotension treatment is being driven by the rising chronic diseases. The prevalence of diabetes, cardiovascular disease, and neurological disorders is increasing worldwide, increasing the risk of O.H. It is connected to the autonomic nerve system becoming dysfunctional. Dehydration is another common condition that increases the risk of O.H. and damages human nerves. The rising older population is one of the main factors driving the market value for orthostatic hypotension.
Orthostatic hypotension and other age-related health issues become more prevalent as people age, necessitating more effective treatment alternatives. The prevalence of chronic diseases like diabetes and heart disease, which can damage nerves and make it harder for the body to control blood pressure, is another factor that increases the likelihood of developing orthostatic hypotension and necessitates treatment. The rising usage of pharmaceuticals that might have orthostatic hypotension as a side effect is another factor propelling the market for orthostatic hypotension drugs. More incidences of orthostatic hypotension occur due to the rising number of people using these drugs, driving up demand for efficient treatment solutions. OH is a chronic, incapacitating illness that might be difficult to treat in certain individuals. Several drugs improve standing time, postural issues, and function.
There may need to be more than just treating OH patients with a single drug since orthostatic stress changes throughout the day. As a result, the utilization of pharmaceutical combinations, such as midazolam and fludrocortisone, midazolam and pyridostigmine, or midazolam and octreotide, is becoming increasingly important in treating symptomatic OH. Combination therapy is considered for patients with OH who are resistant to treatment. It is possible to mix fludrocortisone with midodrine at lower dosages if both drugs are ineffective when used alone.
The market for medications for orthostatic hypotension is predicted to have encouraging expansion throughout the forecast period as a consequence of these therapeutic breakthroughs. A stress test, such as walking on a treadmill, is carried out while exercising. Medication to make the heart work harder may be given to people who cannot exercise. The heart is then monitored by electrocardiography, echocardiography, or other procedures. As a result, these tests are frequently utilized to evaluate a patient's condition for the quickest recovery, which opens up several chances for the procedures involved in medication development.
As the population ages and the incidence of chronic conditions like diabetes and heart disease rises, hypotension is becoming increasingly widespread. Ambulatory blood pressure monitoring is one of the latest diagnostic methods that may be used to identify hypotension. Several public awareness programs have been established to increase public awareness of hypotension. Thanks to these initiatives, people have been made more aware of the illness and the warning signs. Both individuals and medical professionals are becoming more conscious of hypotension. This is a good trend since it indicates that more individuals are getting the diagnosis and the necessary therapy for the illness.The prevalence of hypotension is rising for a variety of causes. The disorder is getting increasingly prevalent, which is one of the causes.
Chronic problems like diabetes and heart disease are more common as the population ages, and these illnesses might raise the risk of hypotension. Creating new diagnostic tools is another factor contributing to the increased awareness of hypotension. The diagnosis of hypotension used to be challenging, but now a variety of modern instruments are available to help with the process. As a result, diagnosing hypotension has become simpler for medical professionals, and public awareness of the disease has increased. Finally, various public awareness efforts have started spreading knowledge about hypotension. Thanks to these initiatives, people have been made more aware of the illness and the warning signs. Thus, driving the Hypotension Treatment market revenue.
Based on products, the Hypotension Treatment market segmentation includes blood pressure transducers, sphygmomanometers, and blood pressure devices. The blood pressure transducers segment dominated the market, accounting for 45% of market revenue. Orthostatic hypotension can be diagnosed using a range of diagnostic methods. The test that is performed the most frequently is the "orthostatic vital signs test," sometimes referred to as the "postural blood pressure test" or "tilt table test." Person's blood pressure and heart rate are measured twice throughout the test: first while lying down and again while standing. The operation is done in a hospital or doctor's office and typically lasts 10 to 15 minutes. Within three minutes of standing, the test measures a systolic blood pressure reduction of at least 20 mm Hg or a diastolic blood pressure reduction of at least 10 mm Hg.
Based on End Users, the Hypotension Treatment market segmentation includes diagnostic centers, home care, hospitals & clinics. The diagnostic centers generated the most income. Many reasons promote the hospital segment in the orthostatic hypotension market, including the availability of many healthcare professionals, speedy treatment choices, and emergency departments. Additionally, the rapid expansion of multi-specialist hospitals and rising investments in the construction of cutting-edge healthcare infrastructure are some important aspects that will fuel sector growth in the years to come.
Figure 1: Hypotension Treatment Market, by End User, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Hypotension Treatment market area will dominate this market; orthostatic hypotension is caused by children and adolescents becoming more obese. Additionally, the availability of medications, higher healthcare expenditure, increasing public awareness of diseases, and improved technology are some of the factors boosting the orthostatic hypotension market's revenue growth in North America.
Further, the major countries studied in the market report are The US, Canada, German, India, Australia, France, the UK, Italy, Spain, South Korea, and Brazil.
Figure 2: HYPOTENSION TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe has the second-largest market share for Hypotension Treatment. The prevalence of certain chronic conditions like medications like antipsychotics, diabetes, and relaxants that raise the risk of orthostatic hypotension. Furthermore, the German Hypotension Treatment market dominated, while the UK Hypotension Treatment market grew fastest in Europe.
From 2023 to 2032, the Asia-Pacific Hypotension Treatment Market will develop at the quickest CAGR. Owing to several causes, including an aging population and increased healthcare costs. Additionally, the market's revenue growth is influenced by adopting healthcare solutions for a higher quality of living, growing health awareness, the incidence of ailments linked to lifestyle, and significant investments in the healthcare sector. Future growth of the market is predicted. Furthermore, China's Hypotension Treatment market had the highest market share, whereas India's Hypotension Treatment market was the Asia-Pacific region's fastest growing.
Hypotension Treatment Key Market Players & Competitive Insights
Leading market companies are extensively spending R&D on increasing their product lines, which will help the Hypotension Treatment market grow even more. Important market developments include new product releases, acquisitions and mergers, contractual agreements, greater investments, and collaboration with other organizations. The Hypotension Treatment industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.
Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Hypotension Treatment industry to serve clients and expand the market sector. The Hypotension Treatment industry has provided some of the most important benefits recently. Church & Dwight., Colgate-Palmolive, and other major companies in the Hypotension Treatment market are aiming to enhance market demand by investing in research and development activities.
Lupin is based in Mumbai, India, an international pharmaceutical firm focusing on innovation. The company creates and promotes a wide variety of branded and biotechnology products, generic formulations, and APIs in more than 100 markets in the Middle East, Asia Pacific, Europe, Latin America, and the United States, including South Africa, India, and the United States. In addition to having a strong presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health sectors, the company holds a leadership position in the anti-diabetic, cardiovascular, and respiratory segments. According to prescriptions, Lupin is the third-largest pharmaceutical firm in the US. In fiscal year 2021, the firm spent 9.6% of its sales on R&D. In June 2021, The United States FDA has given Droxidopa Capsules, 200 mg, 100 mg, and 300 mg, the green light to go on the market.
Key Companies in the Hypotension Treatment market include
A & D medical
Schiller AG
American Diagnostic Corporation
OMRON Corporation
Amgen
Amneal Pharmaceuticals LLC
Apotex, Inc.
Chelsea Therapeutics
F. Hoffman-La Roche
Mylan Inc.
Hypotension Treatment Industry Developments
March 2022: The EMA has given Moxetumomab pasudotox-tdfk orphan medication status for treating adult orthostatic hypotension. Drugs meant to treat uncommon disorders are assigned this classification.
February 2022: Midodrine (Orvaten) now has a new FDA-approved use: treating orthostatic hypotension in kids 6 to 11. A drug called midodrine can assist in tightening blood vessels, which can help to lower blood pressure. Until recently, only persons with orthostatic hypotension were eligible for its use.
Blood Pressure Transducers
Sphygmomanometers
Blood Pressure Devices
Diagnostic Centers
Home Care
Hospitals & Clinics
North America
Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.87 Billion |
| Market Size 2024 | USD 0.95 Billion |
| Market Size 2032 | USD 1.766 Billion |
| Compound Annual Growth Rate (CAGR) | 8.06% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | A & D medical, Schiller AG, American Diagnostic Corporation, Spacelabs Healthcare, and OMRON Corporation. Amgen, Amneal Pharmaceuticals LLC, Apotex, Inc., Chelsea Therapeutics, F. Hoffman-La Roche, H. Lundbeck A/S, Mylan Inc, Novartis AG, Pfizer Inc., and Upsher-Smith Laboratories. |
| Key Market Opportunities | Growing awareness |
| Key Market Dynamics | Growing chronic Diseases |
Hypotension Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
The Hypotension Treatment market size was valued at USD 0.87 Billion in 2023.
The market is projected to grow at a CAGR of 8.06% during the forecast period, 2024-2032.
North America had the largest share in the market
The key players in the market are General Mills Inc., Amway, Conagra Brands Inc., Cargill Incorporated, Abbott Laboratories, Kraft Foods Group Inc., The Coca-Cola Company.
The beverage category dominated the market in 2023.
The store based had the largest share in the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
